APA (7th ed.) Citation

F, M., J, W., L, S., A, C., A, P., R, D., . . . J, K. (2025). Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]. Vaccine, 48, 126628. https://doi.org/10.1016/j.vaccine.2024.126628

Chicago Style (17th ed.) Citation

F, Martinon-Torres, et al. "Corrigendum to "A Phase III, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared with PCV13 in Healthy Infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]." Vaccine 48 (2025): 126628. https://doi.org/10.1016/j.vaccine.2024.126628.

MLA (9th ed.) Citation

F, Martinon-Torres, et al. "Corrigendum to "A Phase III, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared with PCV13 in Healthy Infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]." Vaccine, vol. 48, 2025, p. 126628, https://doi.org/10.1016/j.vaccine.2024.126628.